Mitigating Risk in Implementing Multi-Regional Trials in Multiple Sclerosis

Despite the market authorization of some 16 therapies for multiple sclerosis (MS), there is still no cure for this debilitating disease. In addition, all existing therapies pose safety issues, do not necessarily repair the damage caused by MS, may not have a robust effect on disability, and haveOriginal Article